Your browser doesn't support javascript.
loading
Liver Transplantation for Budd-Chiari Syndrome From Myeloproliferative Neoplasms - Management and Long-Term Results.
Tekbas, Aysun; Schilling, Kristina; Fahrner, René; Morath, Olga; Malessa, Christina; Bauschke, Astrid; Settmacher, Utz; Rauchfuß, Falk.
Afiliación
  • Tekbas A; Department of General, Visceral and Vascular Surgery, Jena University Hospital, Friedrich Schiller University, Jena, Germany; Research Programme "Advanced Clinician Scientist Programme" by the Interdisciplinary Center of Clinical Research of the Medical Faculty Jena, Jena University Hospital, Friedr
  • Schilling K; Department of Hematology and Medical Oncology, Jena University Hospital, Friedrich Schiller University, Jena, Germany.
  • Fahrner R; Spital Thun, Department of General and Visceral Surgery, Thun, Switzerland.
  • Morath O; Department of Hematology and Medical Oncology, Jena University Hospital, Friedrich Schiller University, Jena, Germany; Research Programme "DFG Clinician Scientist Programme Organ Age" by the Interdisciplinary Center of Clinical Research of the Medical Faculty Jena, Jena University Hospital, Friedric
  • Malessa C; Department of General, Visceral and Vascular Surgery, Jena University Hospital, Friedrich Schiller University, Jena, Germany.
  • Bauschke A; Department of General, Visceral and Vascular Surgery, Jena University Hospital, Friedrich Schiller University, Jena, Germany.
  • Settmacher U; Department of General, Visceral and Vascular Surgery, Jena University Hospital, Friedrich Schiller University, Jena, Germany.
  • Rauchfuß F; Department of General, Visceral and Vascular Surgery, Jena University Hospital, Friedrich Schiller University, Jena, Germany.
Transplant Proc ; 56(8): 1759-1765, 2024 Oct.
Article en En | MEDLINE | ID: mdl-39237386
ABSTRACT
Myeloproliferative neoplasms can cause primary Budd-Chiari-Syndrome with acute or chronic liver failure necessitating liver transplantation. However, preventing the recurrence remains challenging and the need for post-transplant anticoagulant and cytoreductive treatment is not sufficiently clear. We analyzed the treatment regimens for all patients who presented to our department with PBCS from MPN between 2004 and 2021. Eight patients underwent liver transplantation - 6 of them due to an acute liver failure. Post-transplant, all patients received anticoagulant and 7 patients cytoreductive medication. The mean survival after transplantation was 13.25 years. Liver transplantation shows favorable long-term outcome when combined with post-transplant anticoagulant and cytoreductive treatment.
Asunto(s)

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Trasplante de Hígado / Síndrome de Budd-Chiari / Trastornos Mieloproliferativos Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Transplant Proc Año: 2024 Tipo del documento: Article

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Trasplante de Hígado / Síndrome de Budd-Chiari / Trastornos Mieloproliferativos Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Transplant Proc Año: 2024 Tipo del documento: Article